In May of 2020 as the Covid-19 pandemic began sweeping the world, Sharon Cummings, Founder and CEO partnered with David Young, Board Of Directors, and Wendy Guy, Chief Management Officer of CorLyst, LLC. together they formed GermArmor. Their mission was to bring to market their lead product, CartArmor.
For many years Ms. Cummings had a vision to create a product to cover up grocery cart handles to protect herself and individuals from contracting other people’s germs – thus CartArmor was born. She had watched people go through the routine of using disposable wipes to clean cart handles, and her thoughts quickly transitioned to a more useful and waste-free product. CartArmor is machine washable with microbial technologies that make it possible to clean and reuse repeatedly.
Ms. Cummings has over 30 years of nursing and dental assistant experience. She began her career in her home state of Vermont working for an Oral Surgeon before going into private practice. Prior to her retirement, she worked for George & Koch Dental for 26 years. She received her nursing degree from Thompson School of Practical Nursing.
Ms. Cummings, and her husband, Graig, retired and relocated to the sunshine and relaxing lifestyle of Florida in 2016. But she has been anything but retired and has now dedicated her life to developing products that promote a germ-free environment for herself, her family, and consumers at-large.
Dr. Young has over 30 years of pharmaceutical research, drug development, corporate experience and is also a serial entrepreneur. His most recent company is CorLyst, LLC – an angel investment firm.
Dr. Young was a Founder and CEO of Promet Therapeutics, LLC since its formation in August 2015. He was Chief Scientific Officer of Questcor Pharmaceuticals from 2009-2014 and was responsible for working with the FDA on modernizing the Acthar Gel label and in obtaining FDA approval in Infantile Spasms. From 2006-2009 prior to joining the executive management team, Dr. Young served as an independent
Director on the Questcor Board of Directors. During the eight years that Dr. Young was involved with Questcor, Questcor transitioned to an orphan drug specialty pharmaceutical company, moving from near bankruptcy in 2007 to a valuation of approximately $5.6 billion in 2014. While serving on Questcor’s Board of Directors, Dr. Young was Executive Director & President, U.S. Operations of AGI Therapeutics plc. Dr. Young has also served as the Executive Vice President of the Strategic Drug Development Division of ICON plc, an international CRO, and was the Founder and CEO of GloboMax LLC, a CRO specializing in FDA drug development, purchased by ICON plc in 2003. Prior to forming GloboMax, Dr. Young was a Tenured Associate Professor at the School of Pharmacy, University of Maryland., where he led a group of 30 faculty, scientists, postdocs, graduate students and technicians in evaluating the biological properties of drugs and drug delivery systems in animals and humans.
Dr. Young received his B.S. in Physiology from the University of California at Berkeley, his M.S. in Medical Physics from the University of Wisconsin at Madison, and his Pharm.D. – Ph.D. with emphasis in Pharmacokinetics and Pharmaceutical Sciences from the University of Southern California.
Prior to her position at Questcor, Ms. Guy was Senior Manager, U.S. Operations of AGI Therapeutics, plc. In this role she was responsible for the day-to-day business and administrative operations of the company. Previously she held multiple senior level positions with the Strategic Drug Development Division of ICON, GloboMax, and Mercer Management Consulting.
Ms. Guy received an A.A. from Mount Wachusett Community College.